AR072596A1 - Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico - Google Patents

Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico

Info

Publication number
AR072596A1
AR072596A1 ARP090102798A ARP090102798A AR072596A1 AR 072596 A1 AR072596 A1 AR 072596A1 AR P090102798 A ARP090102798 A AR P090102798A AR P090102798 A ARP090102798 A AR P090102798A AR 072596 A1 AR072596 A1 AR 072596A1
Authority
AR
Argentina
Prior art keywords
protein
physiologically active
protein complex
polypeptides
active polypeptide
Prior art date
Application number
ARP090102798A
Other languages
English (en)
Inventor
Gwan Sun Lee
Dae Hae Song
Se Chang Kwon
Jae Hee Shin
Mi Ji Lee
Sung Hee Hong
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41570742&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072596(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of AR072596A1 publication Critical patent/AR072596A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe un complejo proteico, que comprende un polipéptido fisiologicamente activo, una proteína dimérica y un polímero no peptídico que tiene tres extremos funcionales (3 brazos), con el enlace tanto del polipéptido fisiologicamente activo como de la proteína dimérica con el polímero no peptídico de 3 brazos mediante respectivas uniones covalentes. El complejo proteico garantiza la actividad de la accion y la bioestabilidad prolongada de un polipéptido fisiologicamente activo. Al tener la capacidad de mantener la bioactividad de los polipéptidos fisiologicamente activos o de los péptidos, de mejorar la semivida sérica de los polipéptidos o péptidos, el complejo proteico puede aplicarse al desarrollo de formulaciones de liberacion sostenida de diversas drogas con polipéptidos fisiologicamente activos. Además, utiliza materias primas que incluyen polipéptidos fisiologicamente activos sin pérdida significativa y, en consecuencia, aumenta el rendimiento de la produccion. También puede ser fácil de purificar. Un método para preparar un complejo proteico y una composicion farmacéutica. Reivindicacion 2: El complejo proteico de acuerdo con la reivindicacion 1, en el cual la proteína dimérica es un dominio del Fc de la inmunoglobulina.
ARP090102798A 2008-07-23 2009-07-23 Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico AR072596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20080071766 2008-07-23

Publications (1)

Publication Number Publication Date
AR072596A1 true AR072596A1 (es) 2010-09-08

Family

ID=41570742

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090102798A AR072596A1 (es) 2008-07-23 2009-07-23 Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico
ARP170102463A AR109513A2 (es) 2008-07-23 2017-09-06 Un complejo proteico, un método para preparar un complejo proteico y una composición farmaceutica que lo comprende

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170102463A AR109513A2 (es) 2008-07-23 2017-09-06 Un complejo proteico, un método para preparar un complejo proteico y una composición farmaceutica que lo comprende

Country Status (22)

Country Link
US (3) US9636420B2 (es)
EP (1) EP2300501B1 (es)
JP (1) JP5563572B2 (es)
KR (1) KR101200659B1 (es)
CN (1) CN102112493B (es)
AR (2) AR072596A1 (es)
AU (1) AU2009274738B2 (es)
BR (1) BRPI0916326A2 (es)
CA (1) CA2731546C (es)
CL (1) CL2011000079A1 (es)
ES (1) ES2523043T3 (es)
HK (1) HK1154023A1 (es)
IL (1) IL210466A (es)
MX (1) MX2011000861A (es)
MY (1) MY151184A (es)
NZ (1) NZ590358A (es)
PE (1) PE20110221A1 (es)
RU (1) RU2483081C2 (es)
TW (1) TWI388570B (es)
UA (1) UA101670C2 (es)
WO (1) WO2010011096A2 (es)
ZA (1) ZA201100157B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE039448T2 (hu) 2004-04-21 2018-12-28 Alexion Pharma Inc Csontba szállító konjugátumok és alkalmazási módszerük a fehérjék csontba juttatására
WO2010011096A2 (en) 2008-07-23 2010-01-28 Hanmi Pharmaceutical Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
AR081755A1 (es) * 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
PE20130206A1 (es) 2010-05-06 2013-02-28 Novartis Ag Anticuerpos multivalentes antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
JP2013527762A (ja) 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）抗体の組成物および使用方法
KR20120002129A (ko) * 2010-06-30 2012-01-05 한미홀딩스 주식회사 면역글로불린 단편을 이용한 제７인자（Ｆａｃｔｏｒ Ⅶａ）약물 결합체
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101303388B1 (ko) * 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CA2930801C (en) 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
IN2013MN02441A (es) 2011-06-28 2015-06-12 Inhibrx Llc
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
MX2014000316A (es) * 2011-07-08 2014-02-19 Bayer Ip Gmbh Proteinas de fusion liberadoras de relaxina y usos de las mismas.
RU2622077C2 (ru) * 2011-09-05 2017-06-09 Ханми Сайенс Ко., Лтд. Фармацевтическая композиция для лечения рака, содержащая конъюгат интерферона-альфа
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
AR090281A1 (es) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101665009B1 (ko) * 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
WO2013148871A1 (en) * 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Engineered polypeptides
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10660940B2 (en) * 2013-03-05 2020-05-26 Hanmi Pharm. Co., Ltd Preparation method for high-yield production of physiologically active polypeptide conjugate
KR101479937B1 (ko) * 2013-05-24 2015-01-12 주식회사 에스에프에이 글라스와 마스크의 정렬장치
AR096891A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
JP6521959B2 (ja) 2013-07-31 2019-05-29 ライナット ニューロサイエンス コーポレイション 操作されたポリペプチドコンジュゲート
MY192248A (en) * 2014-03-31 2022-08-10 Hanmi Pharm Ind Co Ltd Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
SI3134127T1 (sl) 2014-04-25 2020-06-30 Rinat Neuroscience Corp. Konjugati zdravil s protitelesi z visoko stopnjo zdravila
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
JP6983075B2 (ja) 2015-06-02 2021-12-17 ノヴォ ノルディスク アー／エス 極性の組換え延長部を有するインスリン
JP6987741B2 (ja) * 2015-07-24 2022-01-05 ハンミ ファーマシューティカル カンパニー リミテッド 生理活性ポリペプチド結合体の製造方法
KR102644116B1 (ko) 2015-08-17 2024-03-05 알렉시온 파마슈티칼스, 인코포레이티드 알칼린 포스파타제의 제조
CN108136276B (zh) * 2015-09-24 2023-02-28 韩美药品株式会社 通过使用免疫球蛋白片段的特异性位点进行连接的蛋白质复合物
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN
MX2018011833A (es) 2016-04-01 2019-02-13 Alexion Pharma Inc Tratamiento para la debilidad muscular con fosfatasas alcalinas.
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
US11116821B2 (en) 2016-08-18 2021-09-14 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
EP3606560A2 (en) 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
AU2018321359B2 (en) 2017-08-22 2023-11-30 Sanabio, Llc Soluble interferon receptors and uses thereof
CN107540748B (zh) * 2017-09-15 2020-07-14 北京伟杰信生物科技有限公司 长效重组猪fsh融合蛋白及其制备方法与应用
KR101974305B1 (ko) * 2018-02-14 2019-04-30 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
US11267858B2 (en) * 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
WO2022166720A1 (zh) * 2021-02-05 2022-08-11 华南理工大学 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
ES2120949T4 (es) 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
AU660662B2 (en) 1991-02-08 1995-07-06 Progenics Pharmaceuticals, Inc. CD4-gamma2 and CD4-IgG2 chimeras
EP0575545B1 (en) 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
AU2400692A (en) * 1991-07-19 1993-02-23 Hybritech Incorporated Trifunctional compounds having specificity for multi-drug resistant cells
EP0533006A1 (en) 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
US5399671A (en) * 1992-11-18 1995-03-21 Kluger; Ronald Specifically crosslinked hemoglobin with free functionality
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
PT1121382E (pt) 1998-10-16 2006-10-31 Biogen Idec Inc Proteinas de fusao do interferao beta e as respectivas utilizacoes
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
ES2317843T3 (es) 1999-07-13 2009-05-01 Bolder Biotechnology, Inc. Proteinas de fusion de eritropoyetina-inmunoglobulina.
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
CZ308214B6 (cs) 2000-12-07 2020-03-04 Eli Lilly And Company GLP-1 fúzní proteiny
WO2003049684A2 (en) * 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs
US20040023848A1 (en) * 2002-02-27 2004-02-05 Thomas Boehm Compositions for the treatment, prevention, and diagnosis of gastrointestinal and other infections
EP1569690B1 (en) * 2002-12-13 2011-07-27 Mitra Medical Technology AB Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent
JP4870569B2 (ja) * 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
WO2006024953A2 (en) * 2004-08-31 2006-03-09 Pharmacia & Upjohn Company Llc Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
PT1835938E (pt) * 2004-12-27 2013-11-06 Baxter Int Conjugados de polímero-factor de von willebrand
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
RU2428430C2 (ru) * 2005-08-16 2011-09-10 Ханми Холдингс Ко., Лтд. СПОСОБ МАССОВОГО ПРОИЗВОДСТВА ОБЛАСТИ Fc ИММУНОГЛОБУЛИНА С УДАЛЕННЫМИ НАЧАЛЬНЫМИ МЕТИОНИНОВЫМИ ОСТАТКАМИ
US20070117153A1 (en) * 2005-11-23 2007-05-24 Christopher Bieniarz Molecular conjugate
US20090117077A1 (en) * 2006-05-12 2009-05-07 Dong-A Pharm. Co., Ltd. Polyethylene glycol-interferon alpha conjugate
AU2007296056B2 (en) * 2006-09-15 2012-09-13 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
CA2676820A1 (en) * 2007-01-31 2008-08-07 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
WO2010011096A2 (en) 2008-07-23 2010-01-28 Hanmi Pharmaceutical Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends

Also Published As

Publication number Publication date
AU2009274738B2 (en) 2012-12-13
RU2483081C2 (ru) 2013-05-27
WO2010011096A3 (en) 2010-05-27
MY151184A (en) 2014-04-30
WO2010011096A2 (en) 2010-01-28
MX2011000861A (es) 2011-06-21
EP2300501A2 (en) 2011-03-30
ZA201100157B (en) 2011-10-26
US20180360983A1 (en) 2018-12-20
US9636420B2 (en) 2017-05-02
CA2731546C (en) 2013-11-19
US11040110B2 (en) 2021-06-22
TW201004649A (en) 2010-02-01
PE20110221A1 (es) 2011-04-06
CN102112493A (zh) 2011-06-29
JP2011529046A (ja) 2011-12-01
KR101200659B1 (ko) 2012-11-12
IL210466A0 (en) 2011-03-31
EP2300501A4 (en) 2012-02-01
JP5563572B2 (ja) 2014-07-30
CL2011000079A1 (es) 2011-04-29
HK1154023A1 (en) 2012-04-13
ES2523043T3 (es) 2014-11-20
NZ590358A (en) 2012-04-27
TWI388570B (zh) 2013-03-11
CN102112493B (zh) 2015-04-01
US20110200623A1 (en) 2011-08-18
RU2011102446A (ru) 2012-08-27
US10071171B2 (en) 2018-09-11
KR20100010919A (ko) 2010-02-02
EP2300501B1 (en) 2014-08-20
US20160051696A1 (en) 2016-02-25
IL210466A (en) 2013-08-29
AU2009274738A1 (en) 2010-01-28
CA2731546A1 (en) 2010-01-28
UA101670C2 (ru) 2013-04-25
BRPI0916326A2 (pt) 2020-08-25
AR109513A2 (es) 2018-12-19

Similar Documents

Publication Publication Date Title
AR072596A1 (es) Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico
CY1124844T1 (el) Φαρμακευτικο σκευασμα αντισωματος
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
Duan et al. Constructing tunable nanopores and their application in drug delivery
UA106869C2 (uk) Поліпептид ace2
NO2017028I2 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
CY1121042T1 (el) Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως
EA200801460A1 (ru) Рекомбинантные моновалентные антитела и способы их получения
BRPI0518793A2 (pt) mÉtodos para tratar, controlar ou prevenir uma doenÇa ou distérbio de imunodeficiÊncia, e para melhorar a resposta imune a um imunogene, e, composiÇço farmacÊutica
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
ATE405253T1 (de) Gelzusammensetzung mit geladenen polymeren
BR0010750A (pt) Peptìdeos insulinotrópicos de longa duração
CR20140518A (es) Antagonistas neuropilina
EA201890389A3 (ru) Композиции конъюгата xten и способы их получения
ATE385806T1 (de) Fusionsproteine
PE20091405A1 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
DE602006003935D1 (de) Verwendung von Stärke mit abgespaltenen Seitenketten in der Extrudierung / Spheronisierung von pharmazeutischen Pellets
ATE480568T1 (de) Verbesserte sgp 130fc dimere
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
UY31123A1 (es) Proteinas de fusion natriureticas
EA200601905A1 (ru) Микрокапсулы с замедленным высвобождением, основанные на сополимере лактида и гликолида, включающие полипептид и сахар
ATE453666T1 (de) Spezifische monokonjugate von g-csf
BRPI0620436A8 (pt) compostos miméticos de lisina modificados, composição farmacêutica e uso
AR066199A1 (es) Metodo para reducir la concentracion del peptido amiloide beta

Legal Events

Date Code Title Description
FG Grant, registration